Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors

BAYRAKTAR EKİNCİOĞLU, Aygin; TECEN-YUCEL, Kamer; Kılıçkap, Saadettin; erman, mustafa

Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors

Kamer TECEN-YUCEL, (Hacettepe University, Faculty of Pharmacy, Department of Clinical Pharmacy)

SAADETTİN KILIÇKAP, (Hacettepe University, Institute of Cancer, Department of Medical Oncology, Ankara, TURKEY)

Aygin BAYRAKTAR EKİNCİOĞLU, (Hacettepe University, Faculty of Pharmacy, Department of Clinical Pharmacy)

Mustafa ERMAN (Hacettepe University, Institute of Cancer, Department of Medical Oncology, Ankara, TURKEY)

Uluslararası Hematoloji-Onkoloji Dergisi

6 1

Yıl: 2018 Cilt: 28 Sayı: 1 Sayfa Aralığı: 53 - 60 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors

Öz:

Tirozin Kinaz İnhibitörleri ile Tedavi Edilen Onkoloji Hastalarında Klinik Eczacılık UygulamalarıTirozin kinaz inhibitörleri (TKİ), birçok kanser tedavisinde iyi bir etkinlik profiline sahip olmakla birlikte, ilaç etkileşimleri ve advers etkiler açısından da bir risk potansiyeline sahiptir. Bu çalışmanın amacı; tirozin kinaz inhibitörleri kullanan hastalarda klinik eczacının tedavi izlemine katılımı ile ilaç-ilaç etkileşimlerinin ve yan etkilerin saptanması ve değerlendirilmesidir. Bu çalışma Ekim 2015-Nisan 2016 tarihleri arasında bir Üniversite Onkoloji Hastanesinin polikliniğinde gerçekleştirilmiştir. TKİ kullanan hastalar çalışmaya dahil edilmiş ve tedavileri 3 ay boyunca bir klinik eczacı tarafından izlenmiştir. İlaç etkileşimlerinin derecesi ve klinik önemi farklı bilgi kaynakları kullanılarak değerlendirilmiştir. Yan etkiler, birinci ve ikinci vizitlerde değerlendirilmiştir. Çalışmaya 55 hasta dahil edilmiştir. Toplam 92 ilaç etkileşimi saptanmış ve bu etkileşimlerin 54 (%58.69)'ü klinik olarak anlamlı bulunmuştur. Klinik anlamlı bulunan ilaç etkileşimlerinin 18'i ile ilgili olarak eczacı tarafından, doktorlara öneride bulunulmuş ve tüm öneriler kabul edilerek tedavide gerekli değişiklikler yapılmıştır. Üç ay boyunca 55 hastada 32 yan etki etki saptanmış ve buna yönelik 32 öneride bulunulmuş, 29'u (%91) doktorlar tarafından kabul edilmiştir. Gözlenen yan etiler açısından, gastrointestinal rahatsızlıklar (p= 0.001) ve yorgunluk (p= 0.021) gibi yan etkilerin gözlenme sayısında birinci ve ikinci vizitler arasında istatistiksel olarak anlamlı bir azalma saptanmıştır. Hastaların yakın izlemini yapan klinik eczacıların poliklinik bakım hizmetlerine entegre edilmesi, onkolojide multidisipliner ekip ile işbirliği sağlayarak, sağlık hedeflerine daha fazla katkıda bulunabilir

Anahtar Kelime:

Konular: Hematoloji

Tirozin Kinaz İnhibitörleri ile Tedavi Edilen Onkoloji Hastalarında Klinik Eczacılık Uygulamaları

Öz:

Tyrosine kinase inhibitors (TKIs) have a good efficacy profile in treatment of cancers but also have a potential risk for drug interactions and adverse effects. The aim of this study was to identify and evaluate drug-drug interactions and adverse effects related to TKIs in patients by the involvement of a clinical pharmacist within an outpatient setting. This study was conducted at an outpatient clinic of the University Oncology Hospital between October 2015 and April 2016. The patients on TKIs treatment were included and monitored during 3 months by a clinical pharmacist. The severity and a clinical significance of drug interactions were assessed by using different information resources. An occurrence of adverse effects in patients was evaluated in the first and the second visits. Fifty-five patients were included in the study. A total of 92 drug interactions were identified, of those 54 (58.69%) were assessed as a clinically significant. Among clinically significant drug interactions, a pharmacist recommended treatment modifications for 18 drug interactions, all were accepted by doctors and necessary modifications were implemented. Adverse effects (n= 32) were identified in 55 patients during the 3 months where a pharmacist made 32 recommendations, of which 29 (91%) were accepted by doctors. Statistically significant decrease was found in the number of occurred gastrointestinal disorders (p= 0.001) and fatigue (p= 0.021) between the first and the second visits. Close monitoring of patients by clinical pharmacists whom are integrated into the outpatient settings may further contribute to the health outcomes in collaboration with a multidisciplinary team in oncology

Anahtar Kelime:

Konular: Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Li N, Yang L, Ou W, et al. Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer. PLoS One 9: e102777, 2014.
2. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35: 692-706, 2009.
3. Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev 40: 917-926, 2014.
4. Shao J, Markowitz JS, Bei D, An G. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci 103: 3810-3833, 2014.
5. Keller KL, Franquiz MJ, Duffy AP, Trovato JA. Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract, 2016. pii: 1078155216682311. [Epub ahead of print]
6. Leveque D, Delpeuch A, Gourieux B. New anticancer agents: role of clinical pharmacy services. Anticancer Res 34: 1573- 1578, 2014.
7. Haouala A, Widmer N, Duchosal MA, et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117: e75-87, 2011.
8. Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99: 592-600, 2007.
9. Delpeuch A, Leveque D, Gourieux B, Herbrecht R. Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res 35: 457-460, 2015.
10. Yeoh TT, Si P, Chew L. The impact of medication therapy management in older oncology patients. Support Care Cancer 21: 1287-1293, 2013.
11. Kimura M, Go M, Iwai M, et al. Evaluation of the role and usefulness of a pharmacist outpatient service for patients undergoing monotherapy with oral anti-cancer agents. J Oncol Pharm Pract 23: 413-421, 2017.
12. Bremberg ER, Hising C, Nylen U, et al. An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital. J Oncol Pharm Pract 12: 75-81, 2006.
13. Shah S, Dowell J, Greene S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother 40: 1527-1533, 2006.
14. Shah NN, Casella E, Capozzi D, et al. Improving the Safety of Oral Chemotherapy at an Academic Medical Center. J Oncol Pract 12: e71-76, 2016.
15. Moulin SM, Eutropio FJ, Souza JO, et al. The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Support Care Cancer 25: 951-955, 2017.
16. Colombo LRP, Aguiar PM, Lima TM, Storpirtis S. The effects of pharmacist interventions on adult outpatients with cancer: A systematic review. J Clin Pharm Ther 42: 414-424, 2017.
17. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28: 475-480, 2010.
18. Boyer M, Horwood K, Pavlakis N, et al. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol 8: 248-254, 2012.
19. Tassi R, Baldazzi V, Lapini A, et al. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events? Clin Genitourin Cancer 13: e101-105, 2015.
20. LaPlant KD, Louzon PD. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann Pharmacother 44: 1054-60, 2010.
21. Taneja SS. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. J Urol 188: 412-413, 2012.
22. Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs 30: 1055-1064, 2012.
23. Bonifert G, Folkes L, Gmeiner C, et al. Recombinant horseradish peroxidase variants for targeted cancer treatment. Cancer Med 5: 1194-1203, 2016.
24. Bar-Sela G, Cohen M, Ben-Arye, E, Epelbaum R. The Medical use of wheatgrass: review of the gap between basic and clinical applications. Mini Rev Med Chem 15: 1002-10, 2015.
25. Kapoor R, Ronnenberg A, Puleo E, et al. Effects of Pomegranate Juice on Hormonal Biomarkers of Breast Cancer Risk. Nutr Cancer 67: 1113-1119, 2015.

APA	TECEN-YUCEL K, Kılıçkap S, BAYRAKTAR EKİNCİOĞLU A, erman m (2018). Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. , 53 - 60.
Chicago	TECEN-YUCEL Kamer,Kılıçkap Saadettin,BAYRAKTAR EKİNCİOĞLU Aygin,erman mustafa Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. (2018): 53 - 60.
MLA	TECEN-YUCEL Kamer,Kılıçkap Saadettin,BAYRAKTAR EKİNCİOĞLU Aygin,erman mustafa Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. , 2018, ss.53 - 60.
AMA	TECEN-YUCEL K,Kılıçkap S,BAYRAKTAR EKİNCİOĞLU A,erman m Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. . 2018; 53 - 60.
Vancouver	TECEN-YUCEL K,Kılıçkap S,BAYRAKTAR EKİNCİOĞLU A,erman m Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. . 2018; 53 - 60.
IEEE	TECEN-YUCEL K,Kılıçkap S,BAYRAKTAR EKİNCİOĞLU A,erman m "Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors." , ss.53 - 60, 2018.
ISNAD	TECEN-YUCEL, Kamer vd. "Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors". (2018), 53-60.

APA	TECEN-YUCEL K, Kılıçkap S, BAYRAKTAR EKİNCİOĞLU A, erman m (2018). Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. Uluslararası Hematoloji-Onkoloji Dergisi, 28(1), 53 - 60.
Chicago	TECEN-YUCEL Kamer,Kılıçkap Saadettin,BAYRAKTAR EKİNCİOĞLU Aygin,erman mustafa Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. Uluslararası Hematoloji-Onkoloji Dergisi 28, no.1 (2018): 53 - 60.
MLA	TECEN-YUCEL Kamer,Kılıçkap Saadettin,BAYRAKTAR EKİNCİOĞLU Aygin,erman mustafa Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. Uluslararası Hematoloji-Onkoloji Dergisi, vol.28, no.1, 2018, ss.53 - 60.
AMA	TECEN-YUCEL K,Kılıçkap S,BAYRAKTAR EKİNCİOĞLU A,erman m Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. Uluslararası Hematoloji-Onkoloji Dergisi. 2018; 28(1): 53 - 60.
Vancouver	TECEN-YUCEL K,Kılıçkap S,BAYRAKTAR EKİNCİOĞLU A,erman m Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors. Uluslararası Hematoloji-Onkoloji Dergisi. 2018; 28(1): 53 - 60.
IEEE	TECEN-YUCEL K,Kılıçkap S,BAYRAKTAR EKİNCİOĞLU A,erman m "Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors." Uluslararası Hematoloji-Onkoloji Dergisi, 28, ss.53 - 60, 2018.
ISNAD	TECEN-YUCEL, Kamer vd. "Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors". Uluslararası Hematoloji-Onkoloji Dergisi 28/1 (2018), 53-60.